December 20, 2017 / 12:45 PM / 6 months ago

BRIEF-Achillion Initiates Phase I First-In Study Of ACH-5228

Dec 20 (Reuters) - Achillion Pharmaceuticals Inc:

* ACHILLION INITIATES PHASE I FIRST-IN STUDY OF ACH-5228, A NEXT-GENERATION ORAL SMALL MOLECULE INHIBITOR OF COMPLEMENT FACTOR D

* ACHILLION PHARMACEUTICALS INC - COMPANY EXPECTS TO REPORT INTERIM CLINICAL DATA FROM STUDY DURING SECOND HALF OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below